Advertisement

Picture Berlin Partner Berlin-Brandenburg Healthcare Industries Cluster 650x80px
Organisation › Details

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, MOR208, has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 320 employees. *

 

Period Start 1992-01-01 established
  Group MorphoSys (Group)
  Predecessor MorphoSys GmbH
Product Industry biopharmaceutical
Persons Person Kress, Jean-Paul (MorphoSys 201909– CEO before Syntimmune + Biogen + Sanofi Genzyme)
  Person 2 Holstein, Jens (BioNTech 202107– CFO before MorphoSys 201105–202012 CFO before Fresenius Kabi)
     
Region Region Martinsried
  Country Germany
  Street 7 Semmelweisstr.
  City 82152 Planegg
  Tel +49-89-89927-0
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2020-12-31)
  Currency EUR
  Annual sales 327,698,465 (revenues, consolidated (2020) 2020-12-31)
  Profit 97,890,576 (2020-12-31)
  Cash 109,794,680 (2020-12-31)
     
    * Document for �About Section�: MorphoSys AG. (1/31/19). "Press Release: MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab". Planegg.
     
   
Record changed: 2021-08-30

Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

More documents for MorphoSys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Demy-Colton BioFuture 2021 NYC E Hand 650x300px




» top